Company profile: Repare Therapeutics
1.1 - Company Overview
Company description
- Provider of oncology drug discovery and development targeting synthetic lethality, leveraging the SNIPRx CRISPR-based platform to identify gene pairs and develop targeted cancer therapies. Pipeline includes camonsertib (ATR inhibitor), lunresertib (PKMYT1 inhibitor), and preclinical RP-1664 (PLK4) and RP-3467 (Polθ), with ongoing clinical trials.
Products and services
- Camonsertib (RP-3500): An oral small molecule ATR inhibitor developed for treating tumors with specific DNA damage repair-related genomic alterations in various cancers
- Lunresertib (RP-6306): A first-in-class oral small molecule PKMYT1 inhibitor targeting specific genomic alterations in various cancers, developed by Repare Therapeutics for oncology applications
- SNIPRx Platform: A CRISPR-based discovery platform that identifies synthetic lethality gene pairs and develops targeted cancer therapies, enabling precise selection of tumor-specific vulnerabilities for drug development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Repare Therapeutics
Chronix Biomedical
HQ: United States
Website
- Description: Provider of molecular diagnostics leveraging proprietary technology to measure and categorize circulating nucleic acids in blood, developing blood tests to monitor minimal residual disease in cancer patients and supporting diagnosis and management of chronic diseases and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chronix Biomedical company profile →
KEW
HQ: United States
Website
- Description: Provider of personalized oncology management through DNA-based genomic testing and interpretation, including CANCERPLEX profiling of 400+ cancer genes to match targeted therapies; GENEKEEPER variant interpretation software; end-to-end tumor sequencing and personalized reporting; molecular lab enablement for CANCERPLEX; physician sample-to-report services; and patient and caregiver support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KEW company profile →
Genos
HQ: United States
Website
- Description: Provider of a revolutionary approach that brings DNA ownership into your hands and keeps genomic data actionable by connecting you with trusted partners to learn about yourself, help your community, and drive research to better human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genos company profile →
Predicine
HQ: United States
Website
- Description: Provider of genomic profiling tests and algorithms for cancer diagnostics and monitoring, including PredicineATLAS (600-gene NGS with TMB/MSI), PredicineCARE (152-gene cfDNA for treatment selection), PredicineRNA (88-gene cfRNA for fusions/splicing), PredicineHEME (259-gene for hematologic malignancies), PredicineBEACON (MRD tracking), and PredicineWES+ (liquid biopsy exome sequencing for clinical trials).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Predicine company profile →
PathoQuest
HQ: France
Website
- Description: Provider of NGS-based metagenomic tests for exhaustive pathogen identification, offering iDTECT assays and an NGS quality control platform for biologics that deliver actionable reports. Services include adventitious virus testing, identity confirmation, integration site analysis, cell line characterization, and HLA genotyping for cell therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PathoQuest company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Repare Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Repare Therapeutics
2.2 - Growth funds investing in similar companies to Repare Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Repare Therapeutics
4.2 - Public trading comparable groups for Repare Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →